为期 24 周的双盲随机安慰剂对照试验,以评估 LOU064 在青少年中的疗效、PK 和安全性 (12 -
一项双盲、随机、安慰剂对照试验,旨在评估 Remibrutinib (LOU064) 在 12 岁至 18 岁以下青少年中的疗效、药代动力学和安全性,为期 24 周,H1 抗组胺药不能充分控制慢性自发性荨麻疹,随后可选的长达 3 年的开放标签延长期和长达 3 年的可选安全长期免治疗随访期
The purpose of this trial is:
- to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
- to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
- to collect safety data in this population for up to three years after the last dose of study treatment
研究概览
详细说明
This trial consists of 3 different periods:
- the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
- an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
- an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.
The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100050
- Novartis Investigative Site
-
Beijing、中国、100069
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510091
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- Novartis Investigative Site
-
-
-
-
Quebec
-
Montreal、Quebec、加拿大、H4A 3J1
- Novartis Investigative Site
-
-
-
-
-
Cape Town、南非、7925
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria、Gauteng、南非、0181
- Novartis Investigative Site
-
-
-
-
-
Adana、土耳其(türkiye)、01330
- Novartis Investigative Site
-
-
Fatih
-
Istanbul、Fatih、土耳其(türkiye)、34093
- Novartis Investigative Site
-
-
Sihhiye Altindag
-
Ankara、Sihhiye Altindag、土耳其(türkiye)、06230
- Novartis Investigative Site
-
-
-
-
-
Berlin、德国、13353
- Novartis Investigative Site
-
Tübingen、德国、72076
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60590
- Novartis Investigative Site
-
-
-
-
FI
-
Florence、FI、意大利、50139
- Novartis Investigative Site
-
-
PV
-
Pavia、PV、意大利、27100
- Novartis Investigative Site
-
-
SI
-
Siena、SI、意大利、53100
- Novartis Investigative Site
-
-
-
-
Fukuoka
-
Kitakyushu、Fukuoka、日本、8078556
- Novartis Investigative Site
-
-
Kumamoto
-
Kamimashi-gun、Kumamoto、日本、8613106
- Novartis Investigative Site
-
-
Osaka
-
Sakai、Osaka、日本、5938324
- Novartis Investigative Site
-
-
Shimane
-
Izumo、Shimane、日本、6938501
- Novartis Investigative Site
-
-
Tokyo
-
tabashi City、Tokyo、日本、1738610
- Novartis Investigative Site
-
-
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、智利、8420383
- Novartis Investigative Site
-
-
-
-
-
Lodz、波兰、90-436
- Novartis Investigative Site
-
-
-
-
-
Bangkok、泰国、10330
- Novartis Investigative Site
-
Bangkok、泰国、10700
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla、Hat Yai、泰国、90110
- Novartis Investigative Site
-
-
-
-
California
-
Bakersfield、California、美国、93301
- Kern Research
-
San Diego、California、美国、92123
- Allergy and Asthma Medical Group and Research Center
-
-
Florida
-
Miami、Florida、美国、33156
- Pediatric Dermatology of Miami at the Pediatric CoE
-
-
Idaho
-
Boise、Idaho、美国、83706
- Treasure Valley Medical Research
-
-
Illinois
-
Glenview、Illinois、美国、60077
- Endeavor Health
-
-
Kentucky
-
Owensboro、Kentucky、美国、42301
- Allergy and Asthma Specialist P S C
-
-
Ohio
-
Toledo、Ohio、美国、43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Allergy Asthma and Clinical Research
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15241
- Allergy and Clinical Immunology Associates
-
-
Texas
-
San Antonio、Texas、美国、78213
- RFSA Dermatology
-
-
Utah
-
Sandy City、Utah、美国、84093
- Allergy Associates of Utah
-
-
-
-
-
Manchester、英国、M13 9WL
- Novartis Investigative Site
-
Southampton、英国、SO16 6YD
- Novartis Investigative Site
-
-
Cambridgeshire
-
Peterborough、Cambridgeshire、英国、PE3 9GZ
- Novartis Investigative Site
-
-
-
-
-
Utrecht、荷兰、3584 CX
- Novartis Investigative Site
-
-
-
-
-
Valencia、西班牙、46014
- Novartis Investigative Site
-
-
Barcelona
-
Esplugues、Barcelona、西班牙、08950
- Novartis Investigative Site
-
-
-
-
-
CABA、阿根廷、C1181ACH
- Novartis Investigative Site
-
San Miguel de Tucumán、阿根廷、T4000AXL
- Novartis Investigative Site
-
-
Buenos Aires
-
CABA、Buenos Aires、阿根廷、C1414AIF
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000DEJ
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong、Hong Kong、香港、999077
- Novartis Investigative Site
-
-
-
-
Sarawak
-
Kuching、Sarawak、马来西亚、93586
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
- CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
- UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
- Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)
Key Exclusion criteria:
- Previous use of remibrutinib or other BTK inhibitors
- Significant bleeding risk or coagulation disorders
- History of gastrointestinal bleeding
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
- History or current hepatic disease
- Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
- History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
- Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
- Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
- Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1: LOU064 (blinded)
LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks. |
LOU064 (blinded) active treatment
其他名称:
|
|
安慰剂比较:Arm 2: LOU064 placebo (blinded)
LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2) |
matching active drug |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in UAS7
大体时间:Baseline, week 12
|
The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0. Negative change from baseline indicates improvement. |
Baseline, week 12
|
|
Change fron baseline in ISS7
大体时间:Baseline, Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
|
Change from baseline in HSS7
大体时间:Baseline, Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cmax of remibrutinib
大体时间:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The maximum (peak) observed blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Tmax of remibrutinib
大体时间:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The time to reach maximum (peak) blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
AUClast of remibrutinib
大体时间:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Absolute change from baseline in ISS7
大体时间:Baseline - Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Absolute change from baseline in HSS7
大体时间:Baseline - Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Achievement of UAS7 ≤ 6 (yes/no)
大体时间:Week 12 and over time
|
Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Achievement of UAS7 = 0 (yes/no)
大体时间:Week 12 and over time
|
Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Absolute change from baseline in CDLQI score
大体时间:Week 12
|
The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). |
Week 12
|
|
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
大体时间:baseline - Week 12
|
Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity. |
baseline - Week 12
|
|
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
大体时间:28 weeks
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study. |
28 weeks
|
|
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
大体时间:3 years
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study. |
3 years
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CLOU064F12301
- 2022-502159-78-00 (其他标识符:EU CT Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.